The present study first documents the role of miR-26b-5p in liver fibrogenesis and angiogenesis via targeting PDGFR-β, displaying that miR-26b-5p overexpression remarkably inhibits the upregulation of PDGFR-β mRNA and protein levels and attenuates liver fibrosis and angiogenesis in vivo, which can be used as a novel target for the treatment of liver fibrosis. This evidence concerns the gene PDGFRB and Hepatic fibrosis.